Evolut™ TAVR has a differentiated and intentional design.

 

Built on the original CoreValve™ platform, Evolut™ TAVR precisely conforms to the patient’s anatomy, maximizing space for optimal blood flow to consistently deliver large EOAs and low gradients over time. The Evolut™ TAVR proprietary nitinol frame conforms to the annulus for consistent radial force across wide, treatable annulus range.

Supra-annular mounting

Facilitates circularity and maximizes leaflet coaptation for lower gradients and reduced workload on the ventricle.1

Higher outward canted commissures

Distribute mechanical forces to reduce leaflet stress, provide a larger effective orifice area, and minimize prosthesis-patient mismatch (PPM).1

External tissue wrap

Increases surface contact with native anatomy to reduce the risk of paravalvular leak (PVL).2

Four times larger windows

Intended to enable coronary access with the Evolut™ FX+ TAV.†

TAVR risks may include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.

Valve performance matters from day one.

Valve performance helps keep patients alive and out of the hospital.3

Durable valve performance, as defined by freedom from bioprosthetic valve dysfunction (BVD), is critical, regardless of the procedure or platform.

 

Four categories of bioprosthetic valve dysfunction‡

Structural valve deterioration

Occurs years after AVR

Non-structural valve dysfunction

Occurs immediately after AVR

Thrombosis

Occurs unpredictably
anytime after AVR

Endocarditis

Occurs unpredictably
anytime after AVR

Poor valve performance results in worse outcomes.

BVD imparts

↑ 59%

relative increase in hazard
of death or rehospitalization at 5 years.3

Valve performance starts the day of the procedure and continues for a lifetime.

Early performance markers predict late outcomes.

0–30 days

Low gradient and large effective orifice area (EOA)

Freedom from:

Markers of BVD

  • PVL
  • PPM

30 days +

Freedom from:

  • PVL
  • Thrombosis
  • Endocarditis

1 year +

Freedom from:

Structural valve deterioration (SVD)

5 years +

Freedom from:

  • BVD/Bioprosthetic valve failure (BVF)
  • Valve reinterventions

Patients without PPM have a higher survival versus those with severe PPM.4

The Evolut™ TAVR design has a proven legacy of performance.

 

Years of research and rigorous trials have proven the Evolut™ design, establishing it as a clear leader in valve performance compared to both SAVR and other TAVR option.5,6

SMART Trial

Most recently in the SMART Trial, Evolut™ TAVR demonstrated vastly superior valve performance§ vs. SAPIEN™* platform in small annulus◊ patients with excellent early patient outcomes at 1 year.5

 

TAVR risk include, but are not limited to, death, stroke, damage to the arteries, bleeding, and need for permanent pacemaker.

4x less

bioprosthetic valve dysfunction (BVD)‡

Evolut™ TAVR: 9.4%
SAPIEN™* TAVR: 41.6%

For every 10 patients treated with SAPIEN™* TAV, 4 developed BVD. Using the number needed to treat (NNT) from the SMART Trial, of those, 3 could have been avoided if they had been treated with an Evolut™ TAV.7

Explore full evidence summary

↓ 4.4x

less BVD

3.1

NNT

Demonstrating predictable, excellent outcomes

The use of standardized optimized care pathways and cusp overlap with the next generation Evolut™ FX TAV system is associated with low PPI rates and no moderate or severe AR at 30 days.8

 

6.7%

PPI (new onset/worsening CD)
at 30 days.

91%

of Evolut™ FX TAVR patients had none/trace AR and no moderate or greater AR at discharge.

The Evolut™ platform evolves without compromising valve performance.

In partnership with physicians, the Evolut™ design has been meticulously refined and improved to solve unmet needs. Every decision is driven by the relentless pursuit of optimal and durable performance.

CoreValve™
TAV

2007
First self-expanding
TAVR valve

Evolut™ R
TAV

2014
Recapturability, lower profile, and more consistent radial force across annulus range

Evolut™ PRO
TAV

2017
PVL performance

Evolut™ PRO+
TAV

2019#
Lower delivery profile and large valve PVL performance

Evolut™ FX
TAV

2022#

Re-engineered delivery system for improved ease of use and radiopaque markers to reference for deployment depth and commissure location.∆

Evolut™ FX+
TAV

2024#
The latest in a line of rapid innovations on the CoreValve™/Evolut™ platform offering access without compromise.9,10

Explore Evolut™ FX+